+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05856383

Study of Inetetamab with Pyrotinib and Vinorelbine for Treating HER2-Positive Advanced Breast Cancer

Led by Zhejiang Cancer Hospital · Updated on 2023-05-12

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of combining inetetamab with pyrotinib and vinorelbine for treating HER2-positive advanced breast cancer in a real-world setting. This prospective, observational study involves a single group of participants and aims to gather information through patient consent, case collection, and ongoing observation and follow-up. The study is sponsored by Zhejiang Cancer Hospital and focuses on a specific patient population with advanced disease. Participants will receive the combination treatment of inetetamab, pyrotinib, and vinorelbine during the treatment period. The study includes several periods screening, treatment, and survival and follow-up phases. There are no comparison groups or interventions beyond this single treatment approach, and the study does not involve randomization or placebo controls. During participation, individuals will undergo evaluations including tumor progression monitoring and adverse event assessments for up to 48 months. Researchers will measure outcomes such as progression-free survival, overall survival, objective response rate, and disease control rate. The study involves collecting clinical data and following up regularly to assess treatment effects and safety over time.

CONDITIONS

Brief Title

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Research Team

C

Chen zhanhong

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here